Understanding Genome Screening

Genome screening involves analyzing an individual's DNA to identify genetic variations that may influence health and disease susceptibility. This can range from simple single-gene tests to comprehensive whole-genome sequencing. By peering into our genetic blueprint, we can uncover risks for conditions like cancer, diabetes, cardiovascular diseases, and even rare genetic disorders.

The process is straightforward: a saliva or blood sample is collected, and advanced sequencing technologies decipher the genetic code. The results provide a personalized health map, guiding lifestyle modifications, preventive measures, or medical interventions.

A Shift from Reactive to Proactive Healthcare

Traditional healthcare often focuses on treating diseases after they manifest. Genome screening flips this model on its head, enabling a shift toward prevention and early intervention. For instance:

• Cancer Risk Management: Individuals with BRCA1 or BRCA2 gene mutations can opt for enhanced screening programs or preventive surgeries to mitigate their risk of breast and ovarian cancers.

• Cardiovascular Health: Genetic predispositions to conditions like familial hypercholesterolemia can prompt early cholesterol monitoring and lifestyle adjustments.

• Rare Diseases: Identifying carriers of genetic disorders can aid in family planning and reduce the incidence of inherited conditions.

The Ethical and Practical Concerns

While genome screening offers incredible promise, it is not without challenges:

1. Accuracy and Interpretation: Genetic predisposition does not guarantee disease. Misinterpretation of results can lead to unnecessary anxiety or unwarranted medical interventions.

2. Privacy and Data Security: Genetic data is highly sensitive. Ensuring robust data protection measures is crucial to prevent misuse.

3. Accessibility and Equity: High costs and limited availability may restrict access to genome screening, exacerbating health disparities.

Balancing Science and Pseudoscience

The comparison of genome screening to horoscopes isn’t entirely unfounded. Both offer predictive insights, but the scientific foundation of genome screening distinguishes it from astrology. Unlike the alignment of celestial bodies, genetic predictions are based on rigorous data and evidence. However, the probabilistic nature of genetic predispositions underscores the importance of interpreting results in conjunction with clinical and lifestyle factors.

The Road Ahead

As genome screening becomes more affordable and integrated into routine healthcare, its potential to transform lives is immense. Policymakers, healthcare providers, and genetic counselors must collaborate to ensure ethical implementation, public awareness, and equitable access.

Imagine a future where your genetic "horoscope" is a trusted guide, not just a prediction. Early genome screening could help chart a healthier path for generations, making it a cornerstone of personalized medicine. After all, our genes might just hold the key to unlocking a future of better health and well-being.

We have developed panHiTE, a comprehensive and accurate pipeline for TE detection in large-scale population genomes. It has been successfully applied to hundreds of plant population genomes, demonstrating its effectiveness and scalability.

For detailed instructions, please refer to the panHiTE tutorial.

Address of the bookmark: https://github.com/CSU-KangHu/HiTE

“It’s like a subway map,” she said, “but for DNA.”

That idea is exactly what Sequence Tube Map brings to life.

Instead of showing a genome as one long, confusing sequence, it displays different genomic paths like routes on a metro map. Where sequences are shared, the paths travel together. Where genetic variation occurs, they branch into different routes and may join again later.

This makes complex genome graphs much easier to explore.

Maya could now see how different haplotypes moved through the same genomic region and where they took different paths. She could even view sequencing reads mapped onto the graph, helping her understand what was happening in regions with genetic variation.

What once looked like a tangled network now looked like a journey.

Sequence Tube Map turns the complexity of graph genomes into a visual story—making it easier for scientists to see how DNA can take different routes.

Read more at  https://github.com/vgteam/sequencetubemap 

and

https://academic.oup.com/bioinformatics/article/35/24/5318/5542397

Demo at https://vgteam.github.io/sequenceTubeMap/

Instead of asking only whether two genes occur together across genomes, CORGIAS asks a deeper question: did these genes actually evolve together, repeatedly gaining or losing their presence in concert, or are they merely travelling together because of their inherited history? The framework introduces two complementary approaches, Ancestral State Adjustment (ASA) and the Simultaneous EVolution test (SEV), which incorporate evolutionary information into the search for gene associations. This distinction becomes increasingly important as genome sequencing continues to uncover enormous numbers of microbial genomes, many from organisms that have never been cultured and whose genes remain functionally mysterious. In this growing genomic landscape, simply finding a gene is no longer enough—we need clues about what that gene might be doing. CORGIAS approaches this problem almost like a genomic detective: rather than treating every association as evidence, it reconstructs the evolutionary story behind the association and asks whether the evidence survives that history. By doing so, it offers a way to separate coincidence from biological connection and potentially uncover functional relationships hidden within the vast microbial genomic landscape. The broader message is beautifully simple: genes do not evolve in isolation, and understanding what they do may require us to look beyond where they are today and reconstruct how they arrived there. Sometimes, the most important clue in a genome is not the gene itself, but the evolutionary journey it has taken.

More at https://academic.oup.com/nargab/article/7/4/lqaf182/8377910?

For detail : http://www.sciencemag.org/content/341/6143/281

http://www.npr.org/blogs/health/2013/07/18/203298244/worlds-biggest-virus-may-have-ancient-roots

The ongoing 2014 West Africa Ebola outbreak is considered to be the largest and longest outbreak ever recorded of Ebola, killing at least 932 people and infecting more than 1,700 till date since March in Sierra Leone, Guinea, Nigeria and Liberia.

Hence, the World Health Organisation (WHO) on 8 August, 2014 declared the killer Ebola epidemic ravaging parts of West Africa an international health emergency.

Causes

EVD is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. While there are five identified sub-species of Ebolavirus, four viruses cause disease in humans. They are Bundibugyo virus (BDBV), Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV).

The fifth virus, Reston virus (RESTV), is not considered to be disease-causing in humans.

According to WHO, EVD first appeared in 1976 in two simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River from which the disease takes its name.

How does it spread?

It is still unclear how Ebola spreads. However, it is believed that the first pateint becomes infected through contact with an infected animal's body fluids.

Human-to-human transmission can occur through direct contact with blood, organs or other body fluids of infected people or exposure to objects such as needles and syringes that have been contaminated with infected secretions.

Ebola can also be transmitted from men who have recovered from the disease through semen as it is infectious for up to 7 weeks.

Infected dead bodies can spread Ebola as they are still infectious. So mourners who have direct contact with the body of deceased person can also get the disease.

Who is most at risk?

Health-care workers who do not wear appropriate protective clothing and family members who are in close contact with infected people or deceased patients.

Signs and symptoms:

Symptoms may occur between 2 and 21 days after contracting the infection. Common signs of Ebola include:

Fever

Headache

Muscle, abdominal and joint pain

Sore throat

Weakness

Diarrhea

Vomit or cough up blood

Chest pain

Difficulty in breathing and swallowing

Rash

Hiccups

Bleeding inside and outside the body

Prevention

Currently there is no vaccine available for humans. But the infection can be controlled through the use of recommended protective measures such as:

Avoid contacting infected blood or secretions, including from those who are dead .

Using standard precautions for all patients in the healthcare setting.

Sterilizing equipment, and wearing protective clothing including masks, gloves, gowns and goggles.

Washing your hands with soaps or detergents.

Disinfecting your surroundings.

Isolate people who have Ebola symptoms.

Culling of infected animals, with close supervision of burial or incineration of carcasses.

Yet, not travelling to the areas or countries where the virus is found is the best way to avoid Ebola.

Zoonotic Henipavirus

https://pubmed.ncbi.nlm.nih.gov/35921459/

https://www.ncbi.nlm.nih.gov/nuccore/OM069646,,OM069567,OM069568,OM069569,OM069570,OM069571,OM069572,OM069573,OM069574,OM069575,OM069576,OM069577,OM069578,OM069579,OM069580,OM069581,OM069582,OM069583,OM069584,OM069585,OM069586,OM069587,OM069588,OM069589,OM069590,OM069591,OM069592,OM069593,OM069594,OM069595,OM069596,OM069597,OM069598,OM069599,OM069600,OM069601,OM069602,OM069603,OM069604,OM069605,OM069606,OM069607,OM069608,OM069609,OM069610,OM069611,OM069612,OM069613,OM069614,OM069615,OM069616,OM069617,OM069618,OM069619,OM069620,OM069621,OM069622,OM069623,OM069624,OM069625,OM069626,OM069627,OM069628,OM069629,OM069630,OM069631,OM069632,OM069633,OM069634,OM069635,OM069636,OM069637,OM069638,OM069639,OM069640,OM069641,OM069642,OM069643,OM069644,OM069645,OM069646

That is the problem ViralQC (https://github.com/ChengPENG-wolf/ViralQC) aims to solve.

Viral sequences recovered from metagenomic data can be incomplete or contaminated with microbial DNA. ViralQC uses information from both DNA sequences and predicted proteins to detect contamination and estimate how complete a viral contig is.

The authors compared ViralQC with CheckV and found that ViralQC performed particularly well for longer viral contigs, improving contamination detection and completeness estimation in several test cases.

Why does this matter? Because discovering a viral sequence is only the first step. If the sequence is contaminated or incomplete, downstream analyses—such as identifying viral functions or studying evolution—can be misleading.

ViralQC provides a useful quality check before researchers trust the viral genome they have discovered.

In a world where metagenomics is uncovering enormous numbers of unknown viruses, tools like ViralQC help us separate the real viral story from an incomplete or mixed-up one.

More at https://academic.oup.com/bioinformatics/article/42/Supplement_2/btag463/8767288

On this page, you can download high resolution images of our renderings. We made them with transparent background, so that you can use it in your work. As the research progresses, we will keep updating the model as well as the images on this page, so stay tuned!

Address of the bookmark: https://nanographics.at/projects/sars-cov-2/

Bactopia can be split into two main parts: Bactopia Analysis Pipeline, and Bactopia Tools.

Bactopia Analysis Pipeline is the main per-isolate workflow in Bactopia. Built with Nextflow, input FASTQs (local or available from SRA/ENA) are put through numerous analyses including: quality control, assembly, annotation, minmer sketch queries, sequence typing, and more.

Bactopia Tools are a set a independent workflows fo

Address of the bookmark: https://github.com/bactopia/bactopia